BMRN
NASDAQ · Biotechnology
Biomarin Pharmaceutical Inc
$54.06
-0.06 (-0.11%)
Performance
1D
—
1W
—
1M
—
3M
-6.49%
6M
+2.64%
1Y
-8.15%
YTD
-9.07%
Open$54.15
Previous Close$54.12
Day High$54.55
Day Low$53.53
52W High$66.28
52W Low$50.76
Volume—
Avg Volume1.95M
Market Cap10.43B
P/E Ratio29.90
EPS$1.76
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$57.48
Below
SMA 200
$56.51
Below
RSI (14)
80.7
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
31 analysts
Price Target
+133.9% upside
Current
$54.06
$54.06
Target
$126.44
$126.44
$89.21
$126.44 avg
$194.19
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.15B | 2.73B | 1.41B |
| Net Income | 341.06M | 265.99M | -2,303,166 |
| Profit Margin | 10.8% | 10.3% | -0.2% |
| EBITDA | 428.03M | 352.36M | -4,073,088 |
| Free Cash Flow | — | — | -1,983,877 |
| Rev Growth | +15.4% | +15.4% | -7.9% |
| Debt/Equity | 0.10 | 0.10 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |